In a landmark partnership, PGxAI, a leader in AI-powered pharmacogenomics, has joined forces with Najashi Holding, a Riyadh-based healthcare investor, to advance precision medicine in Saudi Arabia. This collaboration supports the Kingdom’s Vision 2030, which aims to transform the country's healthcare system and establish Saudi Arabia as a global leader in medical innovation. The primary goal of the partnership is to integrate AI and genomics into Saudi Arabia’s healthcare infrastructure to improve patient care, optimize treatment outcomes, and drive the adoption of personalized medicine on a national scale.
Click here to know more about Precision Medicine
PGxAI’s platform combines artificial intelligence and genomics to tailor drug selection, reduce adverse reactions, and enhance treatment strategies, all based on individual patients’ genetic profiles. This partnership will enable Saudi healthcare providers to make more informed, precise decisions in patient care, reducing the risk of treatment errors and improving overall outcomes. By leveraging these technologies, the aim is to move beyond traditional one-size-fits-all healthcare and toward a more personalized, data-driven approach to medicine.
Najashi Holding, which has a strong track record of investments in healthcare and biotechnology, will play a crucial role in scaling PGxAI’s technology in Saudi Arabia. The company is set to contribute equity to PGxAI’s $20 million Series A round in 2026 and will leverage its extensive networks in both the public and private sectors to accelerate the integration of personalized care throughout the country. This collaboration will also focus on localizing PGxAI’s platform, ensuring seamless adoption and integration with leading health systems and diagnostic laboratories across Saudi Arabia.
Dr. Mike Zack, CEO and co-founder of PGxAI, expressed that this partnership presents a unique opportunity to harness the power of Saudi Arabia’s growing genomic data to drive healthcare innovation. “By integrating AI, genomics, and real-world data, we are aiming to deliver ultra-precise care to every patient,” Dr. Zack said. “We are committed to ensuring that personalized medicine becomes an accessible and sustainable part of Saudi Arabia's healthcare system.”
Allan Gobbs, executive chairman of PGxAI, emphasized that Najashi Holding’s deep market knowledge and public-private networks make it the ideal partner to help scale precision medicine throughout the Kingdom. “Together, we aim to improve population health, reduce healthcare costs, and position Saudi Arabia as a global leader in preventive healthcare and innovation,” he said.
Dr. Ibrahim Najashi, chairman of Najashi Holding, shared his excitement about the partnership, noting that it aligns perfectly with Saudi Arabia’s Vision 2030 healthcare transformation goals. The partnership will not only advance precision medicine but also contribute to the Kingdom’s Health Sector Transformation Program by enhancing clinical decision-making through the use of digital platforms and genomic data.
This collaboration will help accelerate the adoption of personalized medicine in Saudi Arabia, improve healthcare outcomes, and ensure that the country remains at the cutting edge of global medical innovation, further cementing its role as a leader in precision healthcare.
